Your browser doesn't support javascript.
loading
Increased monocyte count and red cell distribution width as prognostic biomarkers in patients with Idiopathic Pulmonary Fibrosis.
Karampitsakos, Theodoros; Torrisi, Sebastiano; Antoniou, Katerina; Manali, Effrosyni; Korbila, Ioanna; Papaioannou, Ourania; Sampsonas, Fotios; Katsaras, Matthaios; Vasarmidi, Eirini; Papakosta, Despoina; Domvri, Kalliopi; Fouka, Eva; Organtzis, Ioannis; Daniil, Zoe; Dimeas, Ilias; Kirgou, Paraskevi; Gourgoulianis, Konstantinos I; Papanikolaou, Ilias C; Markopoulou, Katerina; Kounti, Georgia; Tsapakidou, Eirini; Papadopoulou, Efthymia; Tatsis, Konstantinos; Gogali, Athena; Kostikas, Konstantinos; Tzilas, Vasilios; Chrysikos, Serafeim; Papiris, Spyridon; Bouros, Demosthenes; Kreuter, Michael; Tzouvelekis, Argyrios.
Afiliación
  • Karampitsakos T; Department of Respiratory Medicine, University Hospital of Patras, Patras, Greece.
  • Torrisi S; Center for Interstitial and Rare Lung Diseases, Pneumology, Thoraxklinik, University of Heidelberg, Heidelberg, Germany.
  • Antoniou K; German Center for Lung Research, Heidelberg, Germany.
  • Manali E; Laboratory of Molecular and Cellular Pneumonology, Department of Respiratory Medicine, Faculty of Medicine, University of Crete, Heraklion, Crete, Greece.
  • Korbila I; 2nd Pulmonary Medicine Department, "ATTIKON" University Hospital, Athens Medical School, National and Kapodistrian University of Athens, Athens, Greece.
  • Papaioannou O; 2nd Pulmonary Medicine Department, "ATTIKON" University Hospital, Athens Medical School, National and Kapodistrian University of Athens, Athens, Greece.
  • Sampsonas F; Department of Respiratory Medicine, University Hospital of Patras, Patras, Greece.
  • Katsaras M; Department of Respiratory Medicine, University Hospital of Patras, Patras, Greece.
  • Vasarmidi E; Department of Respiratory Medicine, University Hospital of Patras, Patras, Greece.
  • Papakosta D; Laboratory of Molecular and Cellular Pneumonology, Department of Respiratory Medicine, Faculty of Medicine, University of Crete, Heraklion, Crete, Greece.
  • Domvri K; Pulmonary Department, Medical School, Aristotle University of Thessaloniki, "G. PAPANIKOLAOU'' General Hospital, Exochi, Thessaloniki, Greece.
  • Fouka E; Pulmonary Department, Medical School, Aristotle University of Thessaloniki, "G. PAPANIKOLAOU'' General Hospital, Exochi, Thessaloniki, Greece.
  • Organtzis I; Pulmonary Department, Medical School, Aristotle University of Thessaloniki, "G. PAPANIKOLAOU'' General Hospital, Exochi, Thessaloniki, Greece.
  • Daniil Z; Pulmonary Department, Medical School, Aristotle University of Thessaloniki, "G. PAPANIKOLAOU'' General Hospital, Exochi, Thessaloniki, Greece.
  • Dimeas I; Department of Respiratory Medicine, Medical School, University of Thessaly, Larissa, Greece.
  • Kirgou P; Department of Respiratory Medicine, Medical School, University of Thessaly, Larissa, Greece.
  • Gourgoulianis KI; Department of Respiratory Medicine, Medical School, University of Thessaly, Larissa, Greece.
  • Papanikolaou IC; Department of Respiratory Medicine, Medical School, University of Thessaly, Larissa, Greece.
  • Markopoulou K; Respiratory Medicine Department, "Corfu General Hospital", Corfu, Greece.
  • Kounti G; Pulmonary Department "G. PAPANIKOLAOU" General Hospital, Thessaloniki, Greece.
  • Tsapakidou E; Pulmonary Department "G. PAPANIKOLAOU" General Hospital, Thessaloniki, Greece.
  • Papadopoulou E; Pulmonary Department "G. PAPANIKOLAOU" General Hospital, Thessaloniki, Greece.
  • Tatsis K; Pulmonary Department "G. PAPANIKOLAOU" General Hospital, Thessaloniki, Greece.
  • Gogali A; Department of Respiratory Medicine, Medical School, University of Ioannina, Ioannina, Greece.
  • Kostikas K; Department of Respiratory Medicine, Medical School, University of Ioannina, Ioannina, Greece.
  • Tzilas V; Department of Respiratory Medicine, Medical School, University of Ioannina, Ioannina, Greece.
  • Chrysikos S; First Academic Department of Pneumonology, Hospital for Thoracic Diseases, "SOTIRIA", Medical School, National and Kapodistrian University of Athens, Athens, Greece.
  • Papiris S; 5th Department of Pneumonology, Hospital for Thoracic Diseases, "SOTIRIA", Athens, Greece.
  • Bouros D; 2nd Pulmonary Medicine Department, "ATTIKON" University Hospital, Athens Medical School, National and Kapodistrian University of Athens, Athens, Greece.
  • Kreuter M; First Academic Department of Pneumonology, Hospital for Thoracic Diseases, "SOTIRIA", Medical School, National and Kapodistrian University of Athens, Athens, Greece.
  • Tzouvelekis A; Center for Interstitial and Rare Lung Diseases, Pneumology, Thoraxklinik, University of Heidelberg, Heidelberg, Germany.
Respir Res ; 22(1): 140, 2021 May 05.
Article en En | MEDLINE | ID: mdl-33952261
ABSTRACT

BACKGROUND:

Idiopathic Pulmonary Fibrosis (IPF) represents a chronic lung disease with unpredictable course.

METHODS:

We aimed to investigate prognostic performance of complete blood count parameters in IPF. Treatment-naïve patients with IPF were retrospectively enrolled from two independent cohorts (derivation and validation) and split into subgroups (high and low) based on median baseline monocyte count and red cell distribution width (RDW).

RESULTS:

Overall, 489 patients (derivation cohort 300, validation cohort 189) were analyzed. In the derivation cohort, patients with monocyte count ≥ 0.60 K/µL had significantly lower median FVC%pred [75.0, (95% CI 71.3-76.7) vs. 80.9, (95% CI 77.5-83.1), (P = 0.01)] and DLCO%pred [47.5, (95% CI 44.3-52.3) vs. 53.0, (95% CI 48.0-56.7), (P = 0.02)] than patients with monocyte count < 0.60 K/µL. Patients with RDW ≥ 14.1% had significantly lower median FVC%pred [75.5, (95% CI 71.2-79.2) vs. 78.3, (95% CI 76.0-81.0), (P = 0.04)] and DLCO%pred [45.4, (95% CI 43.3-50.5) vs. 53.0, (95% CI 50.8-56.8), (P = 0.008)] than patients with RDW < 14.1%. Cut-off thresholds from the derivation cohort were applied to the validation cohort with similar discriminatory value, as indicated by significant differences in median DLCO%pred between patients with high vs. low monocyte count [37.8, (95% CI 35.5-41.1) vs. 45.5, (95% CI 41.9-49.4), (P < 0.001)] and RDW [37.9, (95% CI 33.4-40.7) vs. 44.4, (95% CI 41.5-48.9), (P < 0.001)]. Patients with high monocyte count and RDW of the validation cohort exhibited a trend towards lower median FVC%pred (P = 0.09) and significantly lower median FVC%pred (P = 0.001), respectively. Kaplan-Meier analysis in the derivation cohort demonstrated higher all-cause mortality in patients with high (≥ 0.60 K/µL) vs. low monocyte count (< 0.60 K/µL) [HR 2.05, (95% CI 1.19-3.53), (P = 0.01)].

CONCLUSIONS:

Increased monocyte count and RDW may represent negative prognostic biomarkers in patients with IPF.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Monocitos / Índices de Eritrocitos / Eritrocitos / Fibrosis Pulmonar Idiopática Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Aged / Female / Humans / Male País/Región como asunto: Europa Idioma: En Revista: Respir Res Año: 2021 Tipo del documento: Article País de afiliación: Grecia

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Monocitos / Índices de Eritrocitos / Eritrocitos / Fibrosis Pulmonar Idiopática Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Aged / Female / Humans / Male País/Región como asunto: Europa Idioma: En Revista: Respir Res Año: 2021 Tipo del documento: Article País de afiliación: Grecia